## Edgar Filing: NEKTAR THERAPEUTICS - Form 3/A

#### **NEKTAR THERAPEUTICS**

Form 3/A March 07, 2006

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

**SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person \*

 **DRAPEAU LOUIS** 

C/O NEKTAR

(Last) (First)

THERAPEUTICS, 150 INDUSTRIAL ROAD

(Middle)

(Month/Day/Year)

01/17/2006

Statement

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

NEKTAR THERAPEUTICS [NKTR]

4. Relationship of Reporting

Person(s) to Issuer

Filed(Month/Day/Year)

01/17/2006

(Check all applicable)

Director

10% Owner

\_X\_\_ Officer Other (give title below) (specify below) Sr. VP Finance, CFO

6. Individual or Joint/Group

5. If Amendment, Date Original

Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

SAN CARLOS. CAÂ 94070

(Street)

(City) (State)

1. Title of Security (Instr. 4)

(Zip)

2. Amount of Securities Beneficially Owned

(Instr. 4)

3. Ownership Form:

Table I - Non-Derivative Securities Beneficially Owned

4. Nature of Indirect Beneficial Ownership

(Instr. 5)

Direct (D) or Indirect (I)

(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially

owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security

(Instr. 4)

2. Date Exercisable and **Expiration Date** 

Expiration

Date

(Month/Day/Year)

Exercisable

3. Title and Amount of Securities Underlying **Derivative Security** 

4. Conversion or Exercise

5.

Ownership Form of Derivative

6. Nature of Indirect Beneficial Ownership (Instr. 5)

(Instr. 4)

Title

Amount or Number of Derivative Security

Price of

Security: Direct (D)

1

## Edgar Filing: NEKTAR THERAPEUTICS - Form 3/A

Shares or Indirect

(I) (Instr. 5)

Employee Stock Option (Right to Buy)

(1) 01/17/2016 Common Stock

90,000 \$ 19.59

D Â

# **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

DRAPEAU LOUIS C/O NEKTAR THERAPEUTICS 150 INDUSTRIAL ROAD SAN CARLOS, CAÂ 94070

Â

Â Sr. VP Finance, CFO Â

# **Signatures**

/s/ Louis Drapeau 03/07/2006

\*\*Signature of Date
Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 1/5th of the option shares shall vest on January 17, 2007; the remaining shares shall vest monthly thereafter so that all of the shares shall be fully vested on January 17, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2